Divi’s Laboratories’ (Divi’s) Q1FY24 revenue growth was impacted by severe pricing pressure in Europe though EBITDA margin at 28.3% was broadly in line with the guidance of a sequential recovery. Raw material cost (down 373bps QoQ) has also started softening now.